Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic, progressive condition where the primary treatment goal is to maintain control of glycated haemoglobin (HbA1c). In order for healthcare decision makers to ensure patients receive the highest standard of care within the available budget, the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Charokopou, M., McEwan, P., Lister, S., Callan, L., Bergenheim, K., Tolley, K., Postema, R., Townsend, R., Roudaut, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635987/
https://www.ncbi.nlm.nih.gov/pubmed/26541516
http://dx.doi.org/10.1186/s12913-015-1139-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635987/
https://www.ncbi.nlm.nih.gov/pubmed/26541516
http://dx.doi.org/10.1186/s12913-015-1139-y

Ejemplares similares